Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 7Unknown 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1Lymphoid 1

Conditions

Myelodysplastic Syndromes 1Lymphoma 1Graft vs Host Disease 1

Interventions

Cisplatin 517Radiotherapy 378Cyclophosphamide 368Carboplatin 359Capecitabine 342Paclitaxel 337Oxaliplatin 336Gemcitabine 322Docetaxel 317Fluorouracil 290Drug Therapy 276Bevacizumab 248apatinib 247camrelizumab 219Etoposide 201Irinotecan 182Doxorubicin 181Leucovorin 163Dexamethasone 161pembrolizumab 153Neoadjuvant Therapy 146sintilimab 145anlotinib 140Blood Specimen Collection 140Pemetrexed 138Cytarabine 138toripalimab 133Surgical Procedures, Operative 131Radiosurgery 131S 1 (combination) 125

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Maraviroc × Clear all
NCT02799888 2016-06-15

Maraviroc-Based GVHD Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Transplantation

Affiliated Hospital to Academy of Military Medical Sciences

Phase 2 Unknown
40 enrolled
LymphoidMyeloid

Graft vs Host Disease, Lymphoma, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡